Outlook Therapeutics (OTLK) to Release Quarterly Earnings on Wednesday

Outlook Therapeutics (NASDAQ:OTLKGet Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLKGet Free Report) last announced its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Outlook Therapeutics Price Performance

Shares of NASDAQ:OTLK opened at $1.83 on Wednesday. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85. The stock has a market cap of $58.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.58. The stock’s 50 day moving average price is $1.87 and its 200 day moving average price is $4.81.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on OTLK. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research dropped their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Read Our Latest Analysis on Outlook Therapeutics

Outlook Therapeutics Company Profile

(Get Free Report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Recommended Stories

Earnings History for Outlook Therapeutics (NASDAQ:OTLK)

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.